The project, led by Dutch startup ShanX MedTech, aims to advance these technologies from early innovation towards regulatory-ready solutions. This initiative is part of the EU's strategy to strengthen preparedness for health emergencies and combat antimicrobial resistance, a major global public health challenge.
The developed technology seeks to significantly reduce the time needed to identify the most effective antibiotic treatment, thereby supporting more accurate prescribing decisions and improving patient outcomes. The consortium brings together clinical and industrial partners with extensive experience in in-vitro diagnostics (IVD) and market credibility in point-of-care solutions.
In addition to ShanX MedTech, partners include Aidian Oy (Finland), Biosurfit S.A. (Portugal), and Unitron B.V. (Netherlands). The Spanish team is led by Dr. RAFAEL CANTÓN MORENO, Head of the Biology and Evolution of Microorganisms group at IRYCIS and a leading European expert in the clinical validation of diagnostic technologies for antimicrobial resistance. Dr. PATRICIA RUIZ GARBAJOSA serves as Co-Principal Investigator, and Dr. MARÍA GARCÍA CASTILLO, an expert in technical validation of diagnostic technologies, also participates.
This initiative aligns with the EU's 2017 One Health Action Plan against AMR and the 2023 Council Recommendations, promoting innovation and access to medical countermeasures. IRYCIS highlights the scientific excellence of its microbiology research group, which is instrumental in these European collaborations and aligns with its Strategic Plan ATENEA 2026-2030.
